Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Oct 20;12:714833. doi: 10.3389/fimmu.2021.714833

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2021 Holliday, Earhart, Alnijoumi, Krvavac, Allen and Schrum

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Dornase alfa treatment reduced BALF NETs. Symbols on Day 0 and Day 4 are represented as mean ± SEM of 10 subjects in the bronchoalveolar fluid (BALF) analysis and serum neutrophil extracellular traps (NETs) analysis and 9 subjects in the induced NETs analysis. Due to not having the appropriate material prior to sample collection from the first enrolled patient, we were only able to perform induced NET analysis on 9 subjects (C). Each connecting line with points at Day 0 and 4 represents a unique patient sample and is patient colored coded to previous graphs (N=10). NETs defined by NET MPO : DNA complex measurement was significantly reduced in the BALF after 3 days of therapy with dornase alfa (A). There was no significant change in serum NETs or NETs induced in vitro from patient neutrophils harvested after dornase alfa therapy (B, C) respectively.